Safety in TRIUMPH-1 The safety profile was consistent with incretin-class therapies: Most common AEs (12 mg dose): - Nausea: 42.4% - Diarrhea: 32.0% - Constipation: 26.1% - Vomiting: 25.3% Dysesthesia (a sensory disturbance tingling, numbness) and urinary tract infections were reported in approximately 10% of patients on the highest doses, but were generally mild to moderate and mostly resolved during treatment
Pharmacies must balance supply across patients using these drugs for diabetes and those using them for weight loss, often under conditions where availability, while improved compared to earlier shortages, is still uneven at the local level
The two things that actually stop people: an employer that never bought the weight-loss benefit, and as of June 2026 the uncomfortable headline that Cigna dropped GLP-1 coverage for its own employees
Mom of 1 Used for 7 weeks Verified 90 Day Guarantee Make UNALTERED GLP-1 Support part of your daily routine
Plan limitations may often include quantity limits (usually one pen per month) and restrictions on using multiple GLP-1s together
The fix is not forcing yourself to eat more